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Intraocular fibrin clots caused by uveitis can be a sight-threatening condition which 
needs to be resolved quickly. Intracameral injection of tissue-plasminogen activator 
(tPA) is commonly used to resolve intraocular fibrin. However, the drug does not 
reach fibrinolytic concentrations after topical application. Desmoteplase (DSPA) is a 
structurally similar but smaller fibrinolytic agent with a higher fibrin selectivity, a 
longer half-life, and better biocompatibility compared to tPA. This study was designed 
to evaluate the corneal and scleral permeability of DSPA in rabbits, pigs, dogs, 
horses and humans ex vivo.  
Corneal and scleral tissues were exposed to DSPA in Franz-diffusion chambers. 
Drug concentrations on the receiver side were determined by liquid chromatography 
tandem mass spectrometry.  
Concentrations of DSPA after corneal and scleral permeation through fresh tissues 
ranged from 0.0 to 16.3 µg/ml and 0.0 to 11.4 µg/ml (rabbits), 0.3 to 5.6 µg/ml and 
3.1 to 9.2 µg/ml (dogs), 2.1 to 14.9 µg/ml and 4 to 8.7 µg/ml (horses), 0.6 to 3 µg/ml 
and 2.9 to 18.1 µg/ml (pigs), respectively. A concentration of 0.07 to 12.9 µg/ml 
DSPA was detectable after diffusion through tissue culture preserved human donor 
bank corneas. 
DSPA has the ability to permeate both cornea and sclera ex vivo in all species 
tested. Implications of the ex vivo permeability of DSPA suggest that in vivo 
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Intraokuläres Fibrin, während einer Uveitis, kann das Auge nachhaltig schädigen. 
Deshalb ist eine schnelle Auflösung dieser Gerinnsel notwendig. Die intrakamerale 
Injektion von Gewebsplasminogenaktivator (t-PA) wird zur Auflösung solcher 
Gerinnsel eingesetzt, erreicht jedoch bei topischer Applikation keine fibrinolytisch 
wirksame Konzentration. Desmoteplase (DSPA) ist ein strukturell ähnliches, aber 
kleineres Molekül, welches eine höhere Fibrinselektivität, eine längere Halbwertszeit 
und eine bessere Bioverträglichkeit als t-PA aufweist.  
Die Diffusion durch Kornea und Sklera wurden in Franz-Diffusionszellen getestet. Die 
erreichte Konzentration im Empfängermedium wurde mittels 
Flüssigkeitschromatographie mit Tandem-Massenspektrometrie bestimmt. 
Durchschnittliche DSPA Konzentrationen (+/- Standardabweichung) nach 
Permeation durch Kornea und Sklera betrugen 0.0 bis 16.3 µg/ml und 0.0 bis 11.4 
µg/ml (Kaninchen), 0.3 bis 5.6 µg/ml und 3.1 bis 9.2 µg/ml (Hunde), 2.1 bis 14.9 
µg/ml und 4 bis 8.7 µg/ml (Pferde), 0.6 bis 3 µg/ml und 2.9 bis 18.1 µg/ml 
(Schweine). Eine Konzentration von 0.07 bis 12.9 µg/ml DSPA wurde nach Diffusion 
durch menschliche Hornhäute festgestellt. 
DSPA diffundiert durch Gewebeproben aller getesteten Spezies ex vivo. Die 
Ergebnisse dieser ex vivo Studie implizieren die Möglichkeit einer Diffusion in vivo 
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Purpose: Intracameral injection of tissue-plasminogen activator (tPA) is commonly used to resolve 
intraocular fibrin. The drug does not reach fibrinolytic concentrations after topical application. 
Desmoteplase (DSPA) is a structurally similar but smaller molecule, with a higher fibrin selectivity, a 
longer half-life and better biocompatibility compared to tPA. This ex vivo study was designed to 
evaluate the corneal and scleral permeability of DSPA in rabbits, pigs, dogs, horses and humans.  
Methods: Corneal and scleral tissues (n=5 per group) were inserted into Franz-diffusion chambers and 
exposed to 1.4mg/ml DSPA for 30 min. Drug concentrations on the receiver side were determined by 
liquid chromatography tandem mass spectrometry.  
Results: Concentrations of DSPA after corneal and scleral permeation ranged from 0.0 to 65.4 µg/ml 
and 0.0 to 45.6 µg/ml (rabbits), 1.4 to 22.3 µg/ml and 12.2 to 36.8 µg/ml (dogs), 8.4 to 59.4 µg/ml and 
15.7 to 34.9 µg/ml (horses), 2.4 to 11.8 µg/ml and 11.4 to 72.3 µg/ml (pigs), respectively. 0.3 to 51.6 
µg/ml DSPA was detectable after diffusion through human corneas (table 1). 
Conclusions: DSPA has the ability to permeate cornea and sclera ex vivo in all species examined. The 





Acute, severe uveitis is often observed with fibrinous exudates and a subsequent fibrin clot 
formation is a common complication in both animals and humans. Persistence of fibrinous clots and 
strands can lead to synechiae or obstruct the iridocorneal angle and thus cause secondary glaucoma, 
decrease transparency of ocular media and ultimately cause vision loss 1, 2. Early and efficient lysis of 
intraocular fibrin is therefore of great importance. Treatment with steroids or injections of genetically 
modified (i.e. recombinant) tissue-plasminogen activator (tPA) as a fibrinolytic agent are used to 
dissolve fibrin clots. 
tPA is a direct plasminogen activator (PA), activating plasminogen by cleaving the Arg561-Val562 
bond, resulting in catalytically active plasmin. tPA has low affinity to plasminogen but high affinity to 
fibrin. High concentrations of tPA and plasminogen, which also has a high affinity to fibrin, on the 
surface of fibrin clots lead to lysis of fibrin into soluble split products within approximately 2 hours of 
intracameral injection of tPA. However, tPA causes also limited conversion of plasminogen in the 
absence of fibrin which therefore could lead to systemic haemorrhage 3, 4.  
Due to molecular characteristics, such as size (molecular weight (MW) of 70 kDa) and polarity, tPA 
does not permeate the cornea or sclera in concentrations sufficient to induce intraocular fibrinolysis 
after topical application 4-8. Therefore, tPA must be applied via intraocular injection, which bears a risk 
of infection, increase of inflammation, bleeding, or inadvertent trauma 9. Furthermore, the short tPA 
half-life of 5 minutes cannot prevent re-clotting in case of a persistent inflammatory state of the eye 
which can necessitate multiple injections 7, 8. For intracameral doses exceeding 25 µg tPA, a dose-
dependent toxic effect on retinal and endothelial cells was demonstrated in vitro and in vivo 6, 10-13. 
Desmoteplase (DSPA), originally found in saliva of the strictly blood-feeding vampire bat species 
Desmodus rotundus, is a plasminogen activator, closely related to tPA. 7, 14. DSPAα1, the most fibrin-
specific agent of all four known molecular variants, was ultimately chosen for clinical development. 
Structurally, the molecule is 89% identical with the five classic tPA domains, but is the only PA 
known to exist exclusively as a single chain molecule with full catalytic activity, resulting in a smaller 
molecule size (52 kDa MW) 3, 14. In contrast to tPA, DSPA is an indirect PA which only requires fibrin 
as cofactor for plasminogen activation, consequently granting strictly localized fibrinolytic activity 
with a minimized risk of haemorrhages elsewhere 3, 15-17. DSPA has a 180-fold higher fibrin selectivity 
compared to tPA, which is based on the lack of a plasmin sensitive processing site present in tPA7. 
Compared to tPA’s 5-minute half-life, DSPA has a longer half-life of approximately 3 hours.  
Contrary to tPA, DSPA has shown no neurotoxicity in vitro or in vivo 14, 18-20. Light microscopic 
evaluation of endothelial and retinal cell morphology at 400× magnification has revealed no 
identifiable signs of toxicity after an intracameral injection of DSPA into rabbit eyes 21. Thus, DSPA 
could have advantages over tPA when used for intraocular fibrinolysis, especially in case of sufficient 
fibrinolytic efficacy after topical application.  
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Overcoming ocular barriers is an important issue when administering eye drops as only 1-7% of 
topically instilled drugs penetrate into the anterior chamber 22. Nevertheless, topical administration is a 
preferred route of administration because  it can avoid the traumatic insult, potential iatrogenic 
intraocular bacterial contamination, and the repeated need for sedation associated with intracameral 
injections 23. 
Ocular permeability depends on several parameters. Precorneal factors (solution drainage, blinking, 
tear film composition and turnover) and anatomical barriers including the various layers of the cornea, 
conjunctiva and sclera as well as their thickness and surface area play an important role in drug 
permeation 22-26. The cornea is considered to be the main route of permeation after topical application 
of drugs but larger molecules permeate the eye mainly by diffusion through the sclera 22, 24, 25, 27-30. The 
epithelium with its intercellular tight junctions represents the first barrier to pass; hydrophilic, small 
molecules have been shown to permeate between cells, whereas the transcellular route contributes to 
epithelial transfer of lipophilic drugs. The epithelium is a rate-limiting barrier for highly polar, high-
MW drugs and contributes 90% of the barrier for hydrophilic substances 22, 23. The corneal stroma acts 
as a barrier to lipophilic molecules 26. Endothelial junctions on the other hand are leaky and allow the 
passage of macromolecules 26. Scleral permeability was found to be approximately 10 times higher 
than corneal permeability and is directly proportional to scleral thickness and total surface area 22. 
Interestingly, globular proteins permeate the sclera better than linear dextrans, which makes the 
molecular radius of the applied compound a better predictor of scleral permeability than the MW 22. 
Also, lipophilic or positively charged molecules have shown worse scleral permeability than 
hydrophilic or negatively charged molecules 26. Passive diffusion is the primary route forsolute 
transport and compounds up to 150 kDa MW are able to penetrate the sclera 22. The equatorial region 
of the sclera is significantly thinner and consequently more permeable to macromolecules than the 
posterior segment 28, 30. Considering the molecular size of DSPA, intraocular permeation was expected 
to occur primarily via scleral diffusion.  
For this reason, both transcorneal and transscleral diffusion of DSPA was investigated in ex vivo 
rabbit, canine, equine, porcine, and human tissues in this study.  
2. Materials and methods 
Tissue preparation 
Corneal and scleral tissues of rabbit, porcine, equine and canine eyes, and human corneal tissues were 
collected for experimentation. Fresh rabbit, porcine and equine eyes were obtained from registered 
slaughterhouses in Switzerland. Canine samples were collected with owner consent from animals 
euthanized due to reasons unrelated to the study. All eyes were examined with a focal light source to 
ensure that a normal corneal surface and anterior chamber were present. Corneal de-epithelialization 
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was avoided 31. The globes were stored in Hanks Balanced Salt Solution (HBSS) 32 (Sigma-Aldrich 
Chemie GmbH, Buchs, Switzerland), at 4°C and processed within 4 hours after death. Rabbit, porcine, 
and canine corneas were dissected at the limbus, 10 mm skin biopsy punches (Acu Punch, Acuderm, 
Fort Lauderdale, USA) were used to excise central corneal buttons from the equine eyes as well as 
scleral buttons from all animal species. 
Human corneas were obtained from the donor bank of Inselspital Bern (Bern, Switzerland; donor 
corneas not fitting transplantation criteria). No human scleral tissue was available for this study. The 
human corneas had been stored in Minimum Essential Medium (MEM), 2% foetal bovine serum and 
1% antibiotic solution 33 at 36°C and 5% CO2, and were immersed prior to the experiment in MEM + 
6% dextran solution at 36°C for at least 24 hours to reduce both tissue swelling and volume. 
DSPA concentration 
For the present study, a donor volume of 300 µl and a receptor volume of 5 ml were used. A drug 
permeation of 1% was considered based on the previously reported 1-7% permeation of topically 
instilled drugs into the anterior chamber 22. An intravascular concentration of ≥0.86 µg/ml DSPA was 
determined to lyse intravascular clots most efficiently in a prior study 34. Therefore, a concentration of 
1.4 mg/ml DSPA was chosen for the experiment, translating to 420 µg DSPA in 300 µl donor fluid, as 
this would lead to a concentration of 0.84 µg/ml DSPA (4.2 µg/5ml) in the receiver compartment. 
Permeation experiments 
DSPA was obtained from Lundbeck (Valby, 
Denmark). DSPA permeation experiments in Franz-
type diffusion cells were performed as described 
previously (Fig. 1; SES GmbH – Analysesysteme, 
Bechenheim, Germany) 24, 35.  
The donor compartment was filled with 300 µl of 1.4 
mg/ml DSPA (pH 7.5, 0.027 mmol/l) or Hepes buffer 
for negative controls only (n=2, rabbit cornea and 
sclera). The receiving phase consisted of 5 ml 4-(2-
Hydroxyethyl)-1-piperazineethanesulfonic acid (Hepes 
buffer, 10 mM, pH 7.4, 140 mM NaCl) 12, thermostated at 37°C and stirred with a magnetic bar. 
Tissues were carefully mounted, avoiding remaining air bubbles to optimize the liquid-tissue contact 
zone (0.2 cm2).  
 
 




After 30 minutes of sample exposure to the donor phase solutions, 1 ml samples were collected from 
the receiver compartment 27. Aliquots were taken for analysis and the remaining sample volume was 
frozen at -20°C for future use. The concentrations of DSPA in the receiver compartment solution were 
initially determined via ultraviolet visible spectrometry at 280 nm wavelength, as specified for DSPA 
patent WO2011107299A2. Due to positive ultraviolet visible spectrometry measurement values of 
blank controls at 280 nm this method was considered as insufficiently specific for DSPA.  
The frozen samples (-20°C) were sent to the Functional Genomics Center Zurich for absolute 
quantitation of DSPA by liquid chromatography - tandem mass spectrometry (LC-MS/MS) using 
parallel reaction monitoring (PRM): To identify peptides for PRM, DSPA samples were digested with 
trypsin and then analysed. Detected peptides were searched against the SwissProt database using 
Skyline 36 and the only suitable peptide (DSPA138-146 (GTWSTAESR) was synthesized with 
613C415N-Arg (Sigma-Aldrich Chemie GmbH, Buchs, Switzerland). 
All samples were precipitated with an equal volume of 20% trichloroacetic acid (TCA; Sigma-
Aldrich) and washed twice with cold acetone. The dried pellets were digested with trypsin in 
a microwave instrument (Discover System, CEM) for 30 min at 5 W and 60°C. Digested samples were 
dried again and dissolved in 40 µl 0.1% formic acid (Romil, Cambridge, United Kingdom) containing 
the labeled DSPA138-146 (20 fmol/µl). Samples were analyzed by LC-MS/MS on a nanoAcquity 
UPLC (Waters Inc., Milford, USA) connected to a Q Exactive mass spectrometer (Thermo Fisher 
Scientific). Set masses for the PRM were m/z 497.7331 and 502.7331 for the light and heavy peptide, 
respectively. 
The limit of detection (LOD) of the DSPA138-146 peptide was determined to be < 0.13 pmol 
corresponding to about 6.25 pg of DSPA injected onto the LC column. The limit of quantitation 
(LOQ) was in the range of 1 – 2 fmol DSPA138-146 peptide (about 50 to 100 pg DSPA) on column. 
The linearity interval (R2 = 0.99) ranged from 1 to 80 fmol (about 50 pg – 4 ng DSPA) on column. 
Data Processing 
Absolute concentrations of DSPA were calculated in Skyline 37 by integration of the parent ion signal 
of the peptide DSPA138-146 using the known amount of the synthetic AQUA peptide as internal 
standard.   
Statistical Analysis 
A sample size of n=5 per group was recommended by biostatisticians of the Vetsuisse Faculty 
(detection of disease principle) to provide a ‘yes or no’ answer to the question whether any diffusion 
of DSPA could be measured across corneal and/or scleral tissues. The ex vivo study was designed to 
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determine whether in vivo experiments evaluating the efficacy of topically applied DSPA would be 
justified. Concentrations of DSPA within an eye were assessed using descriptive statistics. 
3. Results 
Concentrations of DSPA after corneal and scleral permeation ranged from 0.0 to 16.3 µg/ml and 0.004 
to 11.4 µg/ml (rabbits), 0.3 to 5.6 µg/ml and 3.1 to 9.2 µg/ml (dogs), 2.1 to 14.9 µg/ml and 4 to 
8.7 µg/ml (horses), 0.6 to 3 µg/ml and 2.9 to 18.1 µg/ml (pigs), respectively. A concentration of 0.07 
to 12.9 µg/ml DSPA was detectable after diffusion through human corneas (Table 1). 
Table 1: Concentrations of DSPA in the samples from the receiver compartment 
tissue Concentration 







rabbit cornea 0.305 16.328 rabbit sclera 0.213 11.396 
0 0 0.059 3.136 
0.162 8.669 0.149 7.981 
0.167 8.933 0 0.004 
0.035 1.875 0.04 2.169 
dog cornea 0.08 4.307 dog sclera 0.117 6.262 
0.016 0.866 0.075 4.025 
0.006 0.339 0.099 5.331 
0.081 4.339 0.161 8.644 
0.034 1.801 0.057 3.045 
0.104 5.571 0.172 9.191 
pig cornea 0.011 0.603 pig sclera 0.072 3.833 
0.051 2.719 0.337 18.085 
0.015 0.784 0.053 2.862 
0.055 2.952 0.122 6.553 
0.02 1.087 0.203 10.889 
0.019 0.996 0.079 4.216 
horse cornea 0.111 5.932 horse sclera 0.073 3.937 
0.103 5.495 0.161 8.604 
0.277 14.861 0.117 6.295 
0.093 4.997 0.095 5.098 
0.039 2.101 0.161 8.639 
0.163 8.722 0.163 8.725 








Our study documents a successful measurement of DSPA after diffusion through ocular tissues of 
different species in Franz-diffusion chambers. The study was conducted as a proof of principle study 
for ethical reasons; in case of negative results, a following in vivo study would not have included 
topical application of DSPA 21. To the authors’ knowledge, this is the first report evaluating the 
permeation of DSPA through corneal and scleral tissues. Permeation of DSPA through the cornea and 
sclera of rabbits, pigs, dogs and horses was demonstrated ex vivo, permeation through long-time stored 
human corneas was most likely influenced by tissue decay. The small number of samples did not 
allow statistical analysis of differences in DSPA permeation between tissues and species. 
The first attempt to measure DSPA via UV/VIS-spectrometry was discarded since positive DSPA 
measurements were also obtained from negative control samples that had not been exposed to DSPA. 
We concluded that corneal and scleral tissue molecules of similar size to DSPA must have influenced 
the results, proving the UV/VIS-spectrometry method inappropriate for measuring DSPA diffusion 
across tissues. Liquid chromatography - tandem mass spectrometry is a very sensitive as well as 
compound-specific measurement method that was able to determine very small amounts of DSPA. 
Concentrations of DSPA could be determined using a DSPA specific heavy amino acid sequence to 
identify DSPA molecules. Blank samples demonstrated negative results when using this technique. 
Permeation of DSPA was observed through both cornea and the sclera. Higher DSPA 
concentrations were expected after diffusion through scleral compared to corneal tissue on the grounds 
of DSPAs molecular size and the fact that larger molecules permeate the eye mainly by scleral 
diffusion22. The current study was not able to support this assumption, which may be explained by the 
small number of samples. Corneal and scleral thickness (rabbit cornea 348-387 µm 38, rabbit sclera 
389.4 ± 4.95 µm 39, canine cornea 606 ± 7.4 µm 40, canine sclera 0.34 ± 0.13 mm 28, equine cornea 
812.0 ± 44.141, equine sclera 0.53 ± 0.1 mm 28, human cornea 560-574 µm 42, human sclera 491 ± 91 
µm 43) as well as surface area vary between species. The results of drug permeability studies can 
therefore not be extrapolated from one species to others 24, 25, 28, 44, 45. Nevertheless, we expected lower 
drug permeation in species with thicker tissues and higher values in species with a thinner cornea and 
sclera. However, those expected trends were not confirmed in this study. The variability across the ex 
vivo drug diffusion measurements might be explained by the small study sample size, combined with 
individual variability in ocular surface barrier anatomy and physiology 45.  
Interestingly, the permeation values obtained through the thicker equine or porcine tissues were 
comparable or even higher than in the other species tested. Precise mounting of 10 mm diameter 
samples was challenging with the thick equine tissues. Correct tissue placement was checked after 
each diffusion experiment. All tissue samples remained in place during the experiment, completely 
covering the opening of the receiver compartment. Only with the relatively thick equine cornea a mild 
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fold in one place of the corneal button was detected in 2/5 specimens. Contamination of the receiver 
compartment with DSPA bypassing the tissue button despite careful sample placement can therefore 
not be excluded completely. A larger button size (>10 mm) and permeation testing of an inert dye as 
a control would therefore be recommended for future studies. 
The extrapolation of results from ex vivo studies to an in vivo situation has been reported to be 
difficult because conjunctival and choroidal blood circulation influence tissue drug concentrations and 
therefore permeation of drugs in in vivo situations 45.  
Equally, the application of DSPA over a 30-minute timeframe did not mirror an in vivo treatment 
situation as tear and aqueous humor turnover, conjunctival absorption, and other factors significantly 
influence drug concentrations in vivo. The concentration gradient of proteins in the eye thus differs 
from concentration gradients in the diffusion chamber. A recent review has described variable 
reproducibility of ex vivo-gained corneal penetration results in in vivo situations using different model 
systems. According to the authors of this review, diffusion cells were likely to overestimate 
transcorneal drug diffusion since the entire cornea is bathed in the drug solution, which can result in 
tissue overhydration and decreased corneal barrier properties 45. In vivo, topically administered drugs 
have a short retention time of 5 minutes that could significantly decrease drug permeation compared to 
the ex vivo situation 46, 47. To reach similarly high drug concentrations in the same time, a multiple 
drug application regimen should be applied in an in vivo follow-up study.  
Despite the difficulties in mimicking an in vivo situation, the 3R principle (replacement, reduction, 
refinement 48) of laboratory animal experiments and animal welfare require exploitation of ex vivo 
systems first to justify intended in vivo trials. 
This study suggests that clinically relevant intraocular concentrations might be reached via topical 
DSPA application in all species tested. Future studies should be designed to test whether permeation 
enhancers or subconjunctival injections could increase diffusion of DSPA. The intraocular 
bioavailability and efficacy of a topically administered drug depend on several factors, including tear 
film and aqueous humour turnover rates, which cannot be evaluated in an ex vivo drug permeation 
study 5, 26. Clinical efficacy remains uncertain since the correlation between ex vivo and in vivo drug 
permeation study results is variable 45. 
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8. Figure Legend 
Fig. 1: Franz diffusion chamber schematic 
 
 
9. Table Legend 
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